Get the Stockscreener App
18.95
3.71%
-0.73
Pre-market:
19.29
0.34
+1.79%
Arcturus Therapeutics Holdings Inc stock is traded at $18.95, with a volume of 944.61K.
It is down -3.71% in the last 24 hours and up +5.34% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
See More
Previous Close:
$19.68
Open:
$19.97
24h Volume:
944.61K
Relative Volume:
1.44
Market Cap:
$514.58M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-16.34
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
-16.00%
1M Performance:
+5.34%
6M Performance:
+102.67%
1Y Performance:
-8.05%
1-Day Range:
$18.37
$20.25
1-Week Range:
$18.37
$22.92
52-Week Range:
$8.04
$23.59
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
18.95 | 534.40M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Is it time to cut losses on Arcturus Therapeutics Holdings Inc.Bond Market & Long-Term Growth Portfolio Plans - newser.com
What technical models suggest about Arcturus Therapeutics Holdings Inc.’s comebackTrade Exit Summary & Safe Capital Investment Plans - newser.com
Arcturus Therapeutics Holdings Inc. stock chart pattern explainedQuarterly Profit Review & Long-Term Capital Growth Strategies - newser.com
Using data models to predict Arcturus Therapeutics Holdings Inc. stock movementMarket Performance Recap & Advanced Technical Signal Analysis - newser.com
What MACD and RSI say about Arcturus Therapeutics Holdings Inc.Fed Meeting & Weekly Momentum Picks - newser.com
Technical analysis overview for Arcturus Therapeutics Holdings Inc. stockJuly 2025 Reactions & Free Daily Entry Point Trade Alerts - newser.com
Arcturus Therapeutics (ARCT) Anticipated to Benefit from Upcomin - GuruFocus
Published on: 2025-10-10 03:52:17 - newser.com
Applying chart zones and confluence areas to Arcturus Therapeutics Holdings Inc.2025 Market Overview & Verified High Yield Trade Plans - newser.com
Arcturus Therapeutics (NASDAQ:ARCT) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
How to use Fibonacci retracement on Arcturus Therapeutics Holdings Inc.Quarterly Performance Summary & Technical Pattern Based Signals - newser.com
Is this a good reentry point in Arcturus Therapeutics Holdings Inc.July 2025 Selloffs & Free High Return Stock Watch Alerts - newser.com
Arcturus Stock Rockets From $9 To $18 In 5 MonthsAll Eyes On Upcoming Cystic Fibrosis Data - RTTNews
Published on: 2025-10-09 02:58:21 - newser.com
Is Arcturus Therapeutics Holdings Inc a good long term investmentChart Pattern Recognition & Double Or Triple Investment - earlytimes.in
Arcturus Therapeutics Holdings Inc Stock Analysis and ForecastBollinger Bands Signals & Investor Community Interactions - earlytimes.in
Public Employees Retirement System of Ohio Makes New Investment in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 4.7%Should You Sell? - MarketBeat
What high frequency data says about Arcturus Therapeutics Holdings Inc.Quarterly Risk Review & Weekly Top Gainers Alerts - newser.com
Real time social sentiment graph for Arcturus Therapeutics Holdings Inc.July 2025 Analyst Calls & Daily Stock Trend Watchlist - newser.com
Does Arcturus Therapeutics Holdings Inc. fit your quant trading modelTrade Risk Summary & Long-Term Capital Growth Ideas - newser.com
Arcturus Therapeutics Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
What dividend safety score for Arcturus Therapeutics Holdings Inc. stockJuly 2025 Decliners & Fast Exit Strategy with Risk Control - newser.com
Best data tools to analyze Arcturus Therapeutics Holdings Inc. stockJuly 2025 Summary & Verified Technical Signals - newser.com
Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap UpHere's What Happened - MarketBeat
High Growth Tech Stocks In The US For September 2025 - simplywall.st
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 9.7%Here's What Happened - MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
How to recover losses in Arcturus Therapeutics Holdings Inc. stock2025 Biggest Moves & Short-Term Trading Opportunity Alerts - newser.com
What drives Arcturus Therapeutics Holdings Inc stock priceCapital Gains Strategies & Small Capital Trading Plans - earlytimes.in
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 7.4%Should You Buy? - MarketBeat
Visualizing Arcturus Therapeutics Holdings Inc. stock with heatmapsPortfolio Value Summary & Low Volatility Stock Suggestions - newser.com
Cathie Wood Just Dumped $3.5 Million in Roku and Roblox For This Hot Stock - parameter.io
Cathie Wood’s ARK Sells Roku and Roblox, Buys Arcturus Stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK Sells Roku and Roblox, Buys Arcturus Stock - Investing.com
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):